To the Editor:
We read with interest the article by Grieco and colleagues (1) on the physiological comparison between high-flow nasal cannula (HFNC) and noninvasive ventilation (NIV) delivered through the helmet in patients with acute hypoxic respiratory failure (AHRF). The optimal noninvasive respiratory support for patients with AHRF is, indeed, a matter of debate, as we are still far from understanding all the mechanisms leading to worsening respiratory failure and intubation (2). Schematically, treatment should aim at minimizing the risk of muscular exhaustion leading to rapid shallow breathing and hypercarbia, while avoiding the risk of additional lung injury, self-inflicted by high transpulmonary pressure and Vt. Noninvasive respiratory support that grants lung- and diaphragm-protective ventilation should then be considered as ideal (3, 4).
The authors should be commended for providing a complete set of physiological data that could enhance our understanding of the effects of different noninvasive support in patients with AHRF. Overall, helmet NIV dramatically decreased the inspiratory effort compared with HFNC. Thus, helmet NIV could be highly efficient in decreasing the diaphragm workload to a desired physiological level, able to protect it from myotrauma and failure (3). On the lung protection side, the authors measured transpulmonary pressure swings (∆PL) as a surrogate of dynamic lung stress during both study phases, reporting nonsignificant differences between HFNC and helmet NIV (Figure 2 of Reference 1, right upper panel; P = 0.11) (1). The reduction in inspiratory effort during helmet NIV might have been due to two different mechanisms: the improvement in respiratory mechanics because of higher positive end-expiratory pressure effect and/or the muscles unloading owing to pressure support. For a given Vt, with the first mechanism, the decrease in inspiratory effort (ΔPes) would be associated with a decrease in ∆Pl (5); on the opposite side, pressure support could decrease ΔPes with unchanged (if mechanics remain stable) or even increased ∆Pl (in the presence of overdistension). Thus, identifying which mechanism is predominant in each patient might help individualize the type of support and NIV settings more than looking at average global values. As an example, it could be interesting to investigate whether the changes in ΔPes and ∆Pl between HFNC and helmet NIV were correlated with end-expiratory transpulmonary pressure during HFNC (6), with subjects with highly negative values experiencing unchanged or even decreased ∆Pl. If this correlation does exist, helmet NIV would be preferred to HFNC in patients with very low end-expiratory transpulmonary pressure. The finding that patients with lower ΔPes during HFNC increased ∆Pl more during helmet NIV could further corroborate this hypothesis: indeed, there was no correlation between ΔPes and oxygenation during HFNC, suggesting that the major determinant of respiratory effort is not altered gas exchange, but rather worse respiratory mechanics and inflammation (4).
The authors also describe that higher ∆Pl during helmet NIV was associated with the need for intubation and with mortality. The latter is undoubtedly an exploratory analysis, but it is interesting to note that seven out of eight patients who ultimately required intubation were clinically supported by helmet NIV for a certain number of hours. It would be interesting to explore whether this might have led to higher lung stress and additional lung injury. Additional explorative analyses could include comparing gas exchange during the study protocol and the last one measured before intubation to check whether lung edema worsened or if derangements of pH and PaCO2 were the main determinants of intubation.
Already, looking at the results, it seems that the ability to limit lung stress by helmet NIV might be lower than during HFNC. Helmet NIV could be considered as step-up support before intubation only in selected patients or if monitoring confirms lung-protective conditions.
Supplementary Material
Footnotes
Originally Published in Press as DOI: 10.1164/rccm.201911-2240LE on December 23, 2019
Author disclosures are available with the text of this letter at www.atsjournals.org.
References
- 1.Grieco DL, Menga LS, Raggi V, Bongiovanni F, Anzellotti GM, Tanzarella ES, et al. Physiological comparison of high-flow nasal cannula and helmet noninvasive ventilation in acute hypoxemic respiratory failure. Am J Respir Crit Care Med. 2020;201:303–312. doi: 10.1164/rccm.201904-0841OC. [DOI] [PubMed] [Google Scholar]
- 2.Rochwerg B, Granton D, Wang DX, Helviz Y, Einav S, Frat JP, et al. High flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure: a systematic review and meta-analysis. Intensive Care Med. 2019;45:563–572. doi: 10.1007/s00134-019-05590-5. [DOI] [PubMed] [Google Scholar]
- 3.Goligher EC, Dres M, Fan E, Rubenfeld GD, Scales DC, Herridge MS, et al. Mechanical ventilation–induced diaphragm atrophy strongly impacts clinical outcomes. Am J Respir Crit Care Med. 2018;197:204–213. doi: 10.1164/rccm.201703-0536OC. [DOI] [PubMed] [Google Scholar]
- 4.Grieco DL, Menga LS, Eleuteri D, Antonelli M. Patient self-inflicted lung injury: implications for acute hypoxemic respiratory failure and ARDS patients on non-invasive support. Minerva Anestesiol. 2019;85:1014–1023. doi: 10.23736/S0375-9393.19.13418-9. [DOI] [PubMed] [Google Scholar]
- 5.Bellani G, Grasselli G, Teggia-Droghi M, Mauri T, Coppadoro A, Brochard L, et al. Do spontaneous and mechanical breathing have similar effects on average transpulmonary and alveolar pressure? A clinical crossover study. Crit Care. 2016;20:142. doi: 10.1186/s13054-016-1290-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Beitler JR, Sarge T, Banner-Goodspeed VM, Gong MN, Cook D, Novack V, et al. EPVent-2 Study Group. Effect of titrating positive end-expiratory pressure (PEEP) with an esophageal pressure-guided strategy vs an empirical high PEEP-Fio2 strategy on death and days free from mechanical ventilation among patients with acute respiratory distress syndrome: a randomized clinical trial. JAMA. 2019;321:846–857. doi: 10.1001/jama.2019.0555. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.